Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies (PAT).
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship Tru Niagen® product portfolio is now third-party verified through the Alkemist Assured™ testing transparency program by Alkemist Labs.
STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit has been granted de novo classification by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.
Esperion announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients.
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company has shipped approximately 440,000 doses of SKYCellflu® to Biogenetech in Thailand from its vaccine manufacturing facility 'L HOUSE' in Andong, South Korea.
Entourage Phytolab, under the leadership of Brazilian entrepreneur Caio Abreu, announces its launch on One Lavi. Known for its commitment to quality and innovation, Entourage Phytolab is set to bring its Entourage Liquid Fusionner™ – Night Use product to the leading online platform for health, beauty, and wellness products.
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Furosemide for Injection in the United States as a therapeutic equivalent generic for Lasix® for Injection (furosemide) approved by the U.S. Food and Drug Administration.
Mirum Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients five years of age and older with progressive familial intrahepatic cholestasis (PFIC).
Pulse Biosciences, Inc. a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its novel CellFX nsPFA Percutaneous Electrode System for use in the ablation of soft tissue in percutaneous and intraoperative surgical procedures.
Mikart, LLC, a leading Contract Development and Manufacturing Organization (CDMO), announces the addition of cutting-edge, Fette® double-sided tablet presses to bolster its production capacity and meet the product demands of its increasing number of clients.